Dermorphin

Dermorphin is a seven-amino-acid peptide (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) first isolated from skin secretions of the South American frog Phyllomedusa sauvagei ¹. It selectively activates the mu-opioid receptor, the same receptor targeted by morphine, and its defining feature is a D-alanine at position 2, a mirror-image amino acid produced by an unusual biological conversion ⁴.

Research interest spans several areas:

• Pain: one historical randomized controlled trial tested intrathecal dermorphin for postoperative pain, and the parent peptide inhibits a spinal pain reflex in humans ².
• Peripheral neuropathic pain: the tetrapeptide analog DALDA has been studied across burn, frostbite, chemotherapy-induced neuropathy, spinal cord injury, and nerve-ligation pain models ⁷.
• Endocrine signaling: dermorphin raises growth hormone and prolactin in human and animal studies ¹⁹.
• Anti-doping and analytical science: detection methods exist for equine plasma and human urine, and seized unlabeled vials containing analogs have been reported ¹⁶.

No modern human clinical development has followed the 1985 trial; the compound remains research-only ².

At the molecular level, dermorphin acts as a full agonist at the mu-opioid receptor, a G protein-coupled receptor that turns on intracellular signaling to suppress pain transmission. Its unnatural D-alanine at position 2 is critical: the L-alanine version binds about one five-thousandth as strongly in rat brain binding assays ³. The N-terminal Tyr-D-Ala-Phe message domain and the C-terminal amide also contribute to receptor recognition ³.

Signaling and functional effects include:

• G protein and ERK/MAPK signaling: dermorphin stimulates GTP binding and ERK phosphorylation in vitro, while suppressing TRPV1-mediated calcium signals in sensory neurons ⁷.
• Receptor internalization: blocking dynamin-dependent endocytosis shifts dermorphin's analgesic dose-response, indicating that receptor internalization contributes to antinociception in the ventrolateral periaqueductal gray ²¹.
• Dose-dependent mu1 versus mu2 effects: low intracerebroventricular doses (10 to 100 pmol/kg) stimulate locomotion and respiration via mu1 receptors, while higher doses produce catalepsy and respiratory depression via mu2 receptors ¹⁸.
• Rapid mu1 desensitization: after intravenous bolus, the apneic response appears only on the first injection, whereas fentanyl triggers it on repeated trials; dermorphin pretreatment blocks fentanyl-induced apnea but not the reverse ⁶.
• Vagal respiratory loop: supranodose vagotomy eliminates dermorphin-evoked respiratory depression in anesthetized rats, localizing the effect to vagal afferent pathways ³⁰.

DALDA is a hydrophilic tetrapeptide designed to stay outside the central nervous system while retaining mu-opioid activity. It inhibits TRPV1-mediated calcium transients in dorsal root ganglion neurons far more than beta-alanine-evoked signals, translating into roughly 70-fold preferential inhibition of heat versus mechanical hypersensitivity ⁷.

Metabolism is peptidase-driven, with the N-terminal tetrapeptide YAFG-OH as the major metabolite in zebrafish and human liver microsomes ¹⁵. The D-alanine residue protects the N-terminus from rapid breakdown ³.

Analgesia in human research. The only controlled human trial, reported in 1985, found intrathecal dermorphin superior to placebo and to morphine for postoperative pain ². Intrathecal dermorphin also inhibits the RIII nociceptive flexion reflex in humans, direct evidence of spinal antinociception ²⁰.

Preclinical pain models. The peripherally restricted analog DALDA has documented effects in multiple independent models:

Model	Reported outcome
Burn pain, rat	Dose-dependent relief of evoked and spontaneous pain without addiction-like behavior 7
Frostbite pain, rat	Reduced mechanical, thermal, and cold hypersensitivity 12
Paclitaxel-induced neuropathy, rat	Normalized pain responses and inflammatory signaling 8
Spinal cord injury, mouse	Attenuated heat hypersensitivity without motor effects 9
Post-spine-surgery pain, rat	Reduced hypersensitivity and sensory neuron hyperexcitability 11
Spinal nerve ligation, rat	Roughly 70-fold greater thermal than mechanical efficacy 10

DALDA also reduces markers of neuroinflammation, including TRPV1, NMDA NR2B, TNF-alpha, IL-1beta, IL-6, and microglial activation, while restoring antioxidant enzymes ⁷.

Other documented effects. Dermorphin elevates growth hormone and prolactin in healthy men ¹⁹. A dermorphin-substance P hybrid improved wound closure and collagen organization in diabetic rats ³¹. Synthetic analogs produce long-lasting analgesia after subcutaneous or intranasal administration in rodents ²⁵.

Respiratory effects. Intravenous bolus dermorphin causes immediate, vagally mediated apnea in rats with recovery around 0.5 minutes, versus about 30 minutes for fentanyl ⁶. Low central doses stimulate respiration, while high central doses depress it ¹⁸.

Human and community patterns. No validated human dosing schedule exists outside a single 1985 intrathecal trial for postoperative pain ². That trial used a single perioperative intrathecal dose, but the exact dose is not indexed in the available literature ². A human experimental study used intrathecal dermorphin to suppress the RIII spinal reflex in single sessions ²⁰. Practitioner-reported research use includes intranasal doses of 20 to 100 micrograms and subcutaneous or intramuscular doses of 250 to 500 micrograms, with onset reported around 5 to 20 minutes and duration of 1 to 3 hours (community protocol).

Preclinical and analog dosing. Most modern dosing data come from animal studies with DALDA and synthetic analogs:

Compound and route	Dose and schedule	Source
DALDA, subcutaneous, burn/frostbite/neuropathy rat models	1, 3, or 10 mg/kg; 10 mg/kg most effective for spontaneous burn pain	7
DALDA, intraperitoneal, rat post-spine-surgery model	5 mg/kg as a single dose at 6 weeks post-injury	11
DALDA, subcutaneous, mouse spinal cord injury	1 mg/kg; blocked by peripheral methylnaltrexone	9
Intranasal analog D2, rat	0.5 to 1.0 micrograms/kg; maximal long-lasting analgesia at 1.0 micrograms/kg with complete stupor	25
AWL3106 wound dressing, diabetic rat	1 mM in lanolin/keratin scaffold, once daily for 21 days	31
Intracerebroventricular dermorphin, rat	10 to 100 pmol/kg stimulates respiration and locomotion; higher doses produce depression	18

These doses are animal-derived and do not translate directly to humans. No modern human repeat-dose protocol has been published ².

Dermorphin and DALDA are water-soluble lyophilized peptides. For subcutaneous or intraperitoneal research preparations, bacteriostatic water (0.9% benzyl alcohol) is the standard diluent in community research practice. For intrathecal research preparations, practitioner consensus favors preservative-free sterile saline, because benzyl alcohol is not appropriate for neuraxial routes.

Storage guidance from the literature and community practice:

• Lyophilized powder: store at -20 degrees C long term or 2 to 8 degrees C short term.
• Reconstituted solution: keep refrigerated at 2 to 8 degrees C and discard after 14 to 30 days.
• Avoid repeated freeze-thaw cycles and inspect for turbidity or precipitation before each draw.

The D-alanine at position 2 protects the N-terminus from aminopeptidase attack, but the peptide is still metabolized by endopeptidases, with the N-terminal tetrapeptide YAFG-OH as the major metabolite in zebrafish and human liver microsome models ⁵. Low-temperature stability has been documented for dermorphin and Hyp6-dermorphin in matrix samples ¹⁶. Seized unlabeled vials containing dermorphin analogs have been reported, so third-party analytical verification is a known consideration in the research supply chain ²⁶.

The interactive calculator in this section can work out specific volumes and concentrations for a given preparation.

Formal clinical drug-interaction studies are absent, but several interactions have been characterized in animal and human mechanistic work.

Opioid antagonists. Naloxone reverses dermorphin-induced catalepsy and prolactin release in animal models ²³. Methylnaltrexone, a peripherally restricted antagonist, abolishes subcutaneous DALDA analgesia ⁹. The mu1-selective antagonist naloxonazine blocks dermorphin-induced apnea ⁶.

Other opioids. Dermorphin pretreatment blocked fentanyl-induced apnea within a two-hour window in rats, while fentanyl did not alter dermorphin responses ⁶. Repeated dermorphin induces tolerance and physical dependence, and cross-tolerance to morphine extends to analgesia and catalepsy ³⁴.

Benzodiazepines and GABAergic agents. Flumazenil antagonizes dermorphin-induced catalepsy, implying GABAergic recruitment downstream of mu2 activation ⁴¹.

Cholinergics. Pirenzepine, a muscarinic antagonist, blocked dermorphin-induced growth hormone release in seven healthy men while sparing prolactin release ¹⁹.

Cardiovascular agents. The dermorphin-ranatensin hybrid LENART01 raised blood pressure in anesthetized rats ²², and hypothalamic microinjection of dermorphin elevated heart rate and blood pressure ⁴⁸.

NSAIDs. The dermorphin analog sedatin protected gastric mucosa against indomethacin-induced injury in rats ⁴⁴. DALDA and ibuprofen each independently reduced frostbite-induced hypersensitivity, but direct combination data are absent ¹².

Gastrointestinal and metabolic interactions. Dermorphin inhibits gastric emptying and intestinal transit in rats ⁴⁶. This could delay absorption of orally co-administered drugs, although no clinical studies test this. CYP-mediated drug interactions are unlikely because dermorphin is cleared by proteolysis rather than CYP enzymes ¹⁵.

No human on/off schedule for dermorphin is established. The only controlled human evidence is a single intrathecal dose in a 1985 perioperative trial, after which development stopped ².

Animal tolerance and dependence. Repeated dermorphin dosing induces tolerance and physical dependence in rats, and cross-tolerance to morphine extends to analgesia and catalepsy ³⁴. A tetrapeptide analog, [D-Arg2, Sar4]-dermorphin(1-4), also produces physical dependence in rats ⁴².

Rapid desensitization. In anesthetized rats, intravenous bolus dermorphin triggers apnea only on the first injection, whereas fentanyl triggers it on repeated trials ⁶. This rapid mu1 desensitization is a distinct feature but does not eliminate tolerance liability with chronic central use ³⁴.

Dose-dependent effects. Low intracerebroventricular doses stimulate respiration and locomotion via mu1 receptors, while higher doses shift to mu2-mediated catalepsy and respiratory depression ¹⁸. This biphasic pattern is the main reason time-boxed, dose-capped cycles are discussed in community sources (community protocol).

Community-derived schedule structures. Practitioner consensus and community protocols suggest acute use periods of 3 to 5 days followed by 7 to 14 days off, with off-periods at least twice the on-period, based on animal tolerance data (community protocol). For rotational use, community sources suggest substituting peripherally restricted MOR agonists such as DALDA or non-opioid analgesics rather than morphine during off periods (practitioner consensus). These are not validated human schedules.

Signs that a research protocol may need a break. In animal and human mechanistic data, fading analgesia at a previously effective dose, sedation or slowed breathing at previously tolerated doses, seizure-like activity after central administration ³⁶, persistent prolactin elevation, and withdrawal symptoms after repeated use are all documented or mechanistically grounded reasons to reassess ⁶.

Most combination evidence comes from engineered hybrid peptides rather than co-administration of separate compounds.

Dermorphin-ranatensin hybrid (LENART01). This hybrid retains human mu-opioid receptor agonism and produces less frequent and less intense apnea than dermorphin alone in anesthetized rats, but it significantly raises blood pressure ¹³.

Dermorphin-substance P hybrid (AWL3106). In diabetic rats, a topical dressing containing this hybrid accelerated wound closure, improved collagen organization, and enhanced vascularization compared with controls ³¹. This suggests dermorphin-based sequences may be compatible with tissue-repair approaches, although direct combination studies with separate repair peptides such as BPC-157 or TB-500 are absent (community protocol).

Growth hormone secretagogues. Dermorphin independently stimulates growth hormone through a central cholinergic pathway in humans ¹⁹. Combining it with GH secretagogues such as ipamorelin, CJC-1295, or MK-677 could exaggerate growth hormone and prolactin pulses; MK-677 already raises prolactin in some users, and dermorphin also elevates prolactin ¹⁹.

GLP-1 receptor agonists. Dermorphin slows gastric emptying and intestinal transit in rats ⁴⁶. GLP-1 agonists such as semaglutide and tirzepatide also slow gastric emptying, so combined use could compound gastrointestinal slowing and delay absorption of oral medications, although no clinical study tests this.

Other mu-opioid peptides and opioids. Shared mu-opioid receptor occupancy accelerates tolerance and dependence; animal data show cross-tolerance with morphine ³⁵. Combining multiple mu-agonists has no evident research rationale and is flagged in community guidance (community protocol).

United States. Dermorphin has no FDA approval for any indication. The only controlled human efficacy dataset is the 1985 intrathecal trial, which was never followed by commercial development ². There is no lawful commercial pharmaceutical supply of dermorphin for human use, and any marketed human product would be an unapproved new drug (practitioner consensus). No DEA scheduling action specific to dermorphin appears in the published literature.

International. No EMA, MHRA, or TGA marketing authorization is documented. Russia is the only jurisdiction with a documented pharmaceutical development track; a quality-control dossier for a dermorphin tetrapeptide was constructed to support regulatory documentation for a non-narcotic analgesic ³⁷. Personal import falls under national unapproved-drug restrictions in all jurisdictions represented in the published literature (practitioner consensus).

Equine sport. Dermorphin is classified as a Racing Commissioners International Class 1 banned substance in equine sport, with LC-MS/MS detection in equine plasma reaching limits of 2 picograms per milliliter for dermorphin and 10 pg/mL for Hyp6-dermorphin ¹⁶. Horse-urine positives have been documented in case reports ²⁶.

Human sport and analytical detection. Anti-doping laboratories have validated human urine methods for dermorphin and its (1-4) fragment at 2.5 ng/mL ¹⁷. A broad UPLC-HRMS screen can detect dermorphin and many other small peptides with limits of 0.010 to 0.473 ng/mL ⁵⁰. The major metabolite YAFG-OH is recommended as the primary target analyte for misuse detection ¹⁵. WADA list categorization is not stated directly in the published literature; laboratories treat dermorphin and its analogs as prohibited peptide analytes (practitioner consensus).

Supply chain. A seized unlabeled vial containing the superpotent analog [Dmt1]-DALDA was reported in 2023, indicating forensic interdiction of dermorphin-class peptides ²⁶.

Respiratory depression and apnea. Intravenous bolus dermorphin produces immediate, vagally mediated mu1-opioid receptor-dependent apnea in anesthetized rats, with recovery around 0.5 minutes compared with about 30 minutes for fentanyl ⁶. Intracerebroventricular doses of 1 to 3 nmol depressed minute volume in rats, and central administration in rabbits produced respiratory depression with bradycardia and hypothermia ¹⁸. The effect is biphasic: low central doses stimulate respiration via mu1 receptors, while high doses depress it via mu2 receptors ¹⁸.

Sedation and catalepsy. The intranasal analog D2 caused complete stupor at 1.0 micrograms/kg in rats ²⁵. Catalepsy from central dermorphin is reversible with naloxone, a TRH analog, or flumazenil ⁴¹. By contrast, subcutaneous DALDA produced no motor deficits or addiction-like behavior in the same neuropathic pain models ⁷.

Seizures. Intracerebroventricular dermorphin triggers epileptiform discharges originating in the ventral hippocampal CA3 region in rats; intravenous administration did not produce such activity ³⁶.

Endocrine effects. Growth hormone and prolactin rise after dermorphin in healthy men, and prolactin release is naloxone-reversible in rats ¹⁹. Chronic hyperprolactinemia carries theoretical risks of galactorrhea, gynecomastia, and hypogonadism, although no clinical reports exist.

Tolerance, dependence, and cardiovascular effects. Repeated dosing induces tolerance and physical dependence in rats, and cross-tolerance to morphine is documented ³⁴. A tetrapeptide analog also produces physical dependence in rats ⁴². In vitro, dermorphin suppressed contractile activity of neonatal rat cardiomyocytes, and the LENART01 hybrid raised blood pressure in anesthetized rats ²².

Contraindications from the literature and consensus. Because of the apnea and respiratory depression data, CNS or respiratory depressants, unmonitored intravenous bolus administration, respiratory insufficiency, seizure disorders, and hyperprolactinemia are flagged as contraindications in the safety literature and community guidance ⁶. No human data exist for pregnancy, breastfeeding, pediatrics, or long-term use, and the absence of data is itself a stated limitation in the literature ².

Open safety questions. No modern repeat-dose human toxicology exists, and the margin between analgesic and respiratory-depressant doses in awake humans is unknown. Human dependence or withdrawal courses have not been studied ².